02559: A Dose Escalation Study of Cannabidiol in Dogs with Epilepsy
Grant Status: Open
Epilepsy is the most common neurologic condition in dogs. Approximately 20-30% of dogs receiving standard therapy remain uncontrolled for seizures. Additionally, the side effects of the antiepileptic drugs (AED) are often unacceptable. Thus, there is a need for an AED that is efficacious with minimal side effects. Cannabidiol (CBD), a prominent non-psychotropic component of the Cannabis sativa plant, has been shown to have anti-convulsant properties in people, offering potential as a treatment for canine epilepsy. The purpose of this study is to find an effective, safe and tolerable dose to reduce seizures in client-owned dogs with uncontrolled epilepsy. The primary goal of the study is to determine an effective and safe dose of CBD for canine epilepsy. If CBD is effective in decreasing seizure frequency, it has the potential to improve quality of life for dogs with uncontrolled epilepsy.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.